Catriona Crossan

Health Economics and Outcomes Research (United Kingdom) — United Kingdom

Medicine · Health Sciences

9h-index491citations36works2.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(13), Health Systems, Economic Evaluations, Quality of Life(8), Hepatitis C virus research(7), Liver Disease and Transplantation(4), Medication Adherence and Compliance(3)

Publications36 total

EE668 Spain Leveling Up: A Comparison of Spain’s New National Health Economic Evaluation Guideline With Those of England, France, Germany, Italy, Portugal, Sweden, Ireland, Canada, Australia, and Japan
Value in Health·2025
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture
Expert Review of Pharmacoeconomics & Outcomes Research·2025
Anti-VEGFs for Diabetic Macular Oedema: Analysis of Efficacy, Safety, and Cost of More Durable Therapies from a Dutch Societal Perspective
Advances in Therapy·2025Open Access
Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective
Expert Review of Pharmacoeconomics & Outcomes Research·2024· 5 cited
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
Expert Review of Vaccines·2024· 10 citedOpen Access
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales
PharmacoEconomics - Open·2024· 2 citedOpen Access
Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis
Liver International·2019· 82 cited
Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial
International Journal of Cardiology·2018· 25 cited
A protocol for an economic evaluation of a polypill in patients with established or at high risk of cardiovascular disease in a UK NHS setting: RUPEE (NHS) study
BMJ Open·2018· 1 citedOpen Access
Referral pathways for patients with non-alcoholic fatty liver disease based on non-invasive fibrosis tests: diagnostic accuracy and cost analysis of a two-tier approach
Journal of Hepatology·2017· 3 cited
Cost effectiveness of case-finding strategies for primary prevention of cardiovascular disease: a modelling study
British Journal of General Practice·2016· 29 citedOpen Access
Cost‐effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the <scp>UK</scp>: systematic review and economic evaluation
Journal of Viral Hepatitis·2015· 26 citedOpen Access
Summary receiver operating characteristic curves
2015
Probability of non-invasive liver tests returning true-positive, false-negative, true-negative or false-positive results
2015
Unit costs of non-invasive liver tests and liver biopsy
2015
Literature review: cost-effectiveness analyses (hepatitis B, hepatitis C, alcoholic liver disease, non-alcoholic liver disease, cirrhosis)
2015
Scatterplots of cost-effectiveness analysis results
2015
Cost-effectiveness analysis: non-alcoholic fatty liver disease
2015
Cost-effectiveness analysis: cirrhosis
2015
Results of systematic review and meta-analysis
2015· 13 cited
page 1 of 2Next →

Frequent Co-authors

Louise Longworth(25), Emmanuel Tsochatzis(24), Kurinchi Selvan Gurusamy(22), Manuel Rodríguez‐Perálvarez(22), Konstantinos Mantzoukis(22), Julia O’Brien(21), Evangelos Thalassinos(19), Vassilios Papastergiou(19), Andrew K. Burroughs(19), Brian Davidson(17), Joanne Lord(5), Brian R Davidson(3), Anna H Noel-Storr(3), Vasilios Papastergiou(3), E. Thalassinos(3), Avik Majumdar(2), Douglas Thorburn(2), William Rosenberg(2), Massimo Pinzani(2), Sarah Willis(2)